Croda Announces the New Pharma Business
Croda recently announced that its Health Care division will now become Croda Pharma, bringing its core speciality excipient portfolio together with the recent acquisition, Avanti Polar Lipids and its Adjuvant Systems arm, all under one business.
Croda Pharma has seen exceptional growth across its high purity excipients and vaccine adjuvants area and more recently announced the acquisition of Avanti Polar Lipids, bringing in a strong pipeline of novel lipids and formulation capabilities in-house.
The company continues to expand its breadth in solutions, enabling over 250 on-going clinical projects, targeting a range of therapeutic areas including oncology, malaria, HIV, and diabetes.
Last week, the company was awarded the prestigious Best Supplier for COVID-19 Vaccine Development at BVOIA Vaccine awards, 2022. The awards give recognition to exceptional biologics and vaccine experts, and technologies that facilitate R&D and biologics manufacturing excellence.
This comes just days after the company announcement of the new strategy and its promise “Empowering biologics delivery” and after Croda Pharma and Avanti Polar Lipids presented at the World Vaccines Congress, Washington DC, on their collaboration and work supporting vaccines globally.
Freek Snieders, Senior Vice President – Croda Pharma, said “This is exactly what Croda is all about – smart science to improve lives. Our great achievements and focus on innovation and deep formulation expertise has continued to propel us forwards as a leading partner for Biopharma. Becoming ‘Croda Pharma’ is a natural progression and represents the joining of three powerful business areas. It represents a single partner that will empower biologics drug delivery for years to come. That is Croda Pharma.”
Croda Pharma continues to expand its offering in innovative speciality excipients, vaccine adjuvant systems, and lipids, in order to support the Biopharma industry with unparalleled quality and expertise.
Established in 1925, Croda is the name behind sustainable, high-performance ingredients and technologies in some of the world’s most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.
Croda is a FTSE 100 company with over 5,500 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart science to improve lives™. As part of this Purpose, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030.
Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next-generation of drug delivery systems. For more information, visit www.croda.com.
Total Page Views: 616